Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma.

about

Indolent lymphoma with composite histology and simultaneous transformation at initial diagnosis exhibit clinical features similar to de novo diffuse large B-cell lymphoma.

P2860

Q55026647-038723EB-A5C0-416C-A806-28A2D859DDC1

P2860

Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma.

Item

http://www.wikidata.org/entity/Q45358673

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Real world data on rituximab m ...... rade 1-3a follicular lymphoma.

@en

Real world data on rituximab m ...... rade 1-3a follicular lymphoma.

@nl

type

Item

label

Real world data on rituximab m ...... rade 1-3a follicular lymphoma.

@en

Real world data on rituximab m ...... rade 1-3a follicular lymphoma.

@nl

prefLabel

Real world data on rituximab m ...... rade 1-3a follicular lymphoma.

@en

Real world data on rituximab m ...... rade 1-3a follicular lymphoma.

@nl

P1476

Real world data on rituximab m ...... grade 1-3a follicular lymphoma

@en

P2093

Hans H Bentzen

http://www.w3.org/2001/XMLSchema#string

Jessica Brady

http://www.w3.org/2001/XMLSchema#string

Kasper L Nielsen

http://www.w3.org/2001/XMLSchema#string

N George Mikhaeel

http://www.w3.org/2001/XMLSchema#string

Peter Braendstrup

http://www.w3.org/2001/XMLSchema#string

Thomas S Larsen

http://www.w3.org/2001/XMLSchema#string

Trung H Do

http://www.w3.org/2001/XMLSchema#string

P2860

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database.

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

P304

297-301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.14775

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

182

http://www.w3.org/2001/XMLSchema#string

P50

Martin Bøgsted

Tarec Christoffer El-Galaly

P577

2017-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28542714

http://www.w3.org/2001/XMLSchema#string

Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma.

about

P2860

P2860

Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698